MarketsNotableReportedDeveloping
4.8
GBL and CVC raise bid for Recordati after shareholder pressure
Le SoirLO·IT · BE·1 day ago
AstraZeneca CEO Pascal Soriot stated in a Bloomberg interview that the company can sustain growth beyond 2030 without a significant acquisition, citing pipeline strength. This signals confidence in organic growth prospects, potentially supporting the stock. The claim is based on CEO commentary, not hard data, so uncertainty remains on execution.